XML 39 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2019
Revenue From Contract With Customer [Abstract]  
Disaggregated Revenues by Timing of Transfer of Goods or Services

The following table presents our revenues, disaggregated by timing of transfer of goods or services (in thousands):

 

 

 

Three Months Ended March 31, 2019

 

 

 

Product Revenue, net

 

 

Collaboration and License Revenue

 

 

Total

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

 

 

 

    Transferred at a point in time

 

$

20,362

 

 

$

 

 

$

20,362

 

    Transferred over time

 

 

 

 

 

1,807

 

 

 

1,807

 

Total

 

$

20,362

 

 

$

1,807

 

 

$

22,169

 

 

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the three months ended March 31, 2019 (in thousands):

 

 

 

Balance at

Beginning of

Period

 

 

Addition

 

 

Deduction

 

 

Balance at End

of Period

 

Contract assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unbilled - collaboration and license revenue

 

$

9,880

 

 

$

1,634

 

 

$

(5,197

)

 

$

6,317

 

Total contract assets

 

$

9,880

 

 

$

1,634

 

 

$

(5,197

)

 

$

6,317

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contract liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

6,335

 

 

$

1,112

 

 

$

(809

)

 

$

6,638

 

Total contract liabilities

 

$

6,335

 

 

$

1,112

 

 

$

(809

)

 

$

6,638

 

Significant changes in the contract liabilities balances during the period are as follows (in thousands):

 

 

 

 

 

 

 

Three Months

Ended as of

March 31, 2019

 

Revenue recognized according to the current period performance that was included in the contract liability at the beginning of the period

 

 

173

 

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2019 (in thousands):

 

Collaborator

 

Transaction Price

Allocated to the

Remaining

Performance

Obligation as of

March 31, 2019

 

 

Expected Year

By Which Revenue

Recognition Will

Be Completed

 

 

Percentage of

Revenue

Recognized

 

BMS and Pfizer - 2016 agreement

 

$

1,525

 

 

 

2021

 

 

 

88

%

Daiichi Sankyo - 2014 agreement

 

 

1,112

 

 

 

2020

 

 

 

97

%

Daiichi Sankyo - 2016 agreement

 

 

3,257

 

 

 

2023

 

 

 

79

%

Bayer - 2016 agreement

 

 

2,911

 

 

 

2023

 

 

 

81

%

Total

 

$

8,805